Testosterone replacement therapy and erectile dysfunction

Int J Impot Res. 2022 Nov;34(7):698-703. doi: 10.1038/s41443-021-00512-w. Epub 2022 Jan 8.

Abstract

Testosterone (T) deficiency and erectile dysfunction (ED) are independently functionally and socially impairing, and their concurrence in men can be challenging to treat. Successful management requires an understanding of the mechanisms through which T underlies normal erectile function. While the literature elucidating some of these mechanisms is vast (e.g., androgen regulation of the activity of nitric oxygen synthase and phosphodiesterase type 5) for others it is scarce (e.g., catalysts of castration-induced corporal fibrosis). The randomized controlled trial data for the efficacy of T replacement as mono- or combination therapy to treat ED has been conflicting. Positive results were frequently not clinically meaningful. Meta-analyses have been helpful in illuminating trends that seem to be promising. Consensus is still lacking in several areas, such as the threshold of low T severity for which replacement therapy is most beneficial; the timing for initiating combination therapy; and the duration of treatment.

Publication types

  • Review

MeSH terms

  • Androgens / therapeutic use
  • Erectile Dysfunction* / drug therapy
  • Hormone Replacement Therapy
  • Humans
  • Male
  • Penile Erection
  • Testosterone / adverse effects

Substances

  • Testosterone
  • Androgens